• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Accelerate Diagnostics Inc.

    11/14/24 3:24:23 PM ET
    $AXDX
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $AXDX alert in real time by email
    SC 13G 1 armistice-axdx093024.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*



    ACCELERATE DIAGNOSTICS, INC.

    (Name of Issuer)

     

    Common Stock, $0.001 par value per share

    (Title of Class of Securities)

     

    00430H201

    (CUSIP Number)

     

     

    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  00430H201
     SCHEDULE 13G
    Page 2 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Armistice Capital, LLC
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    2,400,000
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    2,400,000
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    2,400,000
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.93%
    12
    TYPE OF REPORTING PERSON
     
    IA, OO

     


     

    CUSIP No.  00430H201
     SCHEDULE 13G
    Page 3 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Steven Boyd
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States of America
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    2,400,000
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    2,400,000
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    2,400,000
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.93%
    12
    TYPE OF REPORTING PERSON
     
    IN, HC

     


     

     

    CUSIP No. 00430H201
     SCHEDULE 13G
    Page 4 of 8 Pages

     

    Item 1.(a) Name of Issuer

    ACCELERATE DIAGNOSTICS, INC.

    Item 1.(b) Address of Issuer’s Principal Executive Offices

    3950 South Country Club Road, Suite 470

    Tucson, Arizona 85714

    Item 2.(a) Names of Person Filing:

    Armistice Capital, LLC

    Steven Boyd

    Collectively, the "Reporting Persons"

      

    Item 2.(b) Address of Principal Business Office:

     

    Armistice Capital, LLC

    510 Madison Avenue, 7th Floor

    New York, New York 10022

    United States of America

     

    Steven Boyd

    c/o Armistice Capital, LLC

    510 Madison Avenue, 7th Floor

    New York, New York 10022

    United States of America

      

    Item 2.(c) Citizenship:

     

    Armistice Capital, LLC - Delaware

    Steven Boyd - United States of America

      

    Item 2.(d) Title of Class of Securities

     

    Common Stock, $0.001 par value per share (“Shares”)

     

    Item 2.(e) CUSIP No.:

    00430H201

     

    CUSIP No.  00430H201
     SCHEDULE 13G
    Page 5 of 8 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) x A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

    CUSIP No. 00430H201
     SCHEDULE 13G
    Page 6 of 8 Pages

     

     

    Item 4. Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a) Amount beneficially owned as of September 30, 2024:

    Armistice Capital, LLC - 2,400,000

    Steven Boyd - 2,400,000   

    (b) Percent of Class as of September 30, 2024:

    Armistice Capital, LLC - 9.93%

    Steven Boyd - 9.93% 

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote

    Armistice Capital, LLC - 0

    Steven Boyd - 0 

    (ii) Shared power to vote or to direct the vote

    Armistice Capital, LLC - 2,400,000

    Steven Boyd - 2,400,000  

    (iii) Sole power to dispose or to direct the disposition of

    Armistice Capital, LLC - 0

    Steven Boyd - 0 

    (iv) Shared power to dispose or to direct the disposition of

    Armistice Capital, LLC - 2,400,000

    Steven Boyd - 2,400,000

    The percentage of Shares reported to be beneficially owned by the Reporting Persons are based on information from the Issuer.

    Armistice Capital, LLC (“Armistice Capital”) is the investment manager of Armistice Capital Master Fund Ltd. (the "Master Fund"), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund. Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund. The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

     

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    The Master Fund, a Cayman Islands exempted company that is an investment advisory client of Armistice Capital, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
    CUSIP No. 00430H201
     SCHEDULE 13G
    Page 7 of 8 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 14, 2024

     

     

     

     

    Armistice Capital, LLC

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

    Managing Member

           

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

           

     

     
    CUSIP No. 00430H201
     SCHEDULE 13G
    Page 8 of 8 Pages

     

    Exhibit I

     

    JOINT FILING STATEMENT

     

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Dated: November 14, 2024

     

     

    Armistice Capital, LLC

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

    Managing Member

           
     

     
      By:  /s/ Steven Boyd
       

    Steven Boyd

           
    Get the next $AXDX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AXDX

    DatePrice TargetRatingAnalyst
    3/9/2022$5.00Buy → Hold
    Craig-Hallum
    More analyst ratings

    $AXDX
    Financials

    Live finance-specific insights

    See more
    • Accelerate Diagnostics Submits WAVE System and Gram-Negative Positive Blood Culture Menu to the FDA for 510(k) Clearance

      TUCSON, Ariz., March 21, 2025 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX), an innovator in rapid in vitro diagnostics for microbiology, today announced the submission of its Accelerate WAVE™ system and positive blood culture gram-negative test kit to the U.S. Food and Drug Administration (FDA) for 510(k) clearance. The Accelerate WAVE system is designed to provide rapid antimicrobial susceptibility testing (AST) directly from positive blood culture bottles and bacterial isolate colonies. The WAVE system is designed to deliver accurate results in an average of 4.

      3/21/25 1:52:00 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2024 Financial Results

      TUCSON, Ariz., March 21, 2025 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today reports financial results for the fourth quarter and year ended December 31, 2024. 2024 Fourth Quarter Results Net sales for the quarter were $2.8 million, compared to $3.0 million for the same quarter of the prior year. The decline in revenues was primarily driven by lower sales of consumable products compared to the same period in the prior year.Gross margin was approximately 16% for the quarter, compared to approximately 21% for the same quarter of the prior year. The decline in

      3/21/25 8:30:00 AM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Accelerate Diagnostics Announces Certain Preliminary Fourth Quarter and Full-Year 2024 Results

      TUCSON, Ariz., Jan. 10, 2025 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) (Accelerate), an in vitro diagnostics company dedicated to providing services that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections, today announced certain preliminary, unaudited results for the quarter and year ended December 31, 2024. "During the fourth quarter, we continued our momentum across our innovation pipeline with significant progress of the clinical trial for our Accelerate WAVE™ system and the Gram-Negative assay while also

      1/10/25 4:05:00 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AXDX
    SEC Filings

    See more
    • Accelerate Diagnostics Inc. filed SEC Form 8-K: Leadership Update

      8-K - Accelerate Diagnostics, Inc (0000727207) (Filer)

      5/28/25 4:10:50 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form NT 10-Q filed by Accelerate Diagnostics Inc.

      NT 10-Q - Accelerate Diagnostics, Inc (0000727207) (Filer)

      5/16/25 5:27:55 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Accelerate Diagnostics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Accelerate Diagnostics, Inc (0000727207) (Filer)

      5/12/25 4:16:21 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AXDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Accelerate Diagnostics Inc.

      SC 13D/A - Accelerate Diagnostics, Inc (0000727207) (Subject)

      12/5/24 5:13:13 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by Accelerate Diagnostics Inc.

      SC 13G - Accelerate Diagnostics, Inc (0000727207) (Subject)

      11/14/24 3:24:23 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13D/A filed by Accelerate Diagnostics Inc.

      SC 13D/A - Accelerate Diagnostics, Inc (0000727207) (Subject)

      8/12/24 5:01:09 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AXDX
    Leadership Updates

    Live Leadership Updates

    See more
    • Accelerate Diagnostics announces departure of CFO Steve Reichling and appointment of David Patience as replacement

      TUCSON, Ariz., March 14, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) a leading provider of innovative rapid diagnostic solutions, announced today that Steve Reichling will be stepping down as Chief Financial Officer (CFO), effective March 31, 2023. David Patience, who previously served as Senior Director - Head of Business Development and Strategic Finance has been named as the company's new CFO, effective April 1, 2023. Reichling, who has been with the company since 2012, played a vital role in Accelerate Diagnostics' growth and success over the years. Dur

      3/14/23 8:33:00 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Accelerate Diagnostics announces appointment of Hany Massarany to Chairman of Board of Directors

      TUCSON, Ariz., March 8, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) a disruptor in bloodstream infection identification and susceptibility testing today announced the appointment of Hany Massarany to chairman of the company's board of directors effective February 22, 2023. Jack Phillips, Chief Executive Officer of Accelerate Diagnostics, stated, "I am excited for Hany to step into this very important role as Chairman. Hany brings a wealth of leadership and strategic vision, focused on diagnostics and infectious disease testing, which is vital as we grow our

      3/8/23 8:30:00 AM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AXDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Patience John bought $314,000 worth of shares (200,000 units at $1.57) (SEC Form 4)

      4 - Accelerate Diagnostics, Inc (0000727207) (Issuer)

      12/3/24 8:48:49 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Strobeck Matthew bought 100,000 shares (SEC Form 4)

      4 - Accelerate Diagnostics, Inc (0000727207) (Issuer)

      1/25/24 4:12:05 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Francesconi Louise bought 13,333 shares, increasing direct ownership by 176% to 20,927 units (SEC Form 4)

      4 - Accelerate Diagnostics, Inc (0000727207) (Issuer)

      1/25/24 4:11:07 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AXDX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Accelerate Diagnostics Files for Chapter 11 Protection and Agrees to Terms to Sell Substantially All Assets

      TUCSON, Ariz., May 8, 2025 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) ("Accelerate" or the Company") today announced that it has voluntarily initiated a Chapter 11 restructuring proceeding in the United States Bankruptcy Court for the District of Delaware ("Bankruptcy Court") and will seek to sell its assets through a court supervised sale process. Accelerate has filed various "first day" motions with the Bankruptcy Court requesting customary relief that will enable the Company to transition into Chapter 11 without material disruption to their ordinary course o

      5/8/25 9:00:00 AM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Accelerate Diagnostics Submits WAVE System and Gram-Negative Positive Blood Culture Menu to the FDA for 510(k) Clearance

      TUCSON, Ariz., March 21, 2025 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX), an innovator in rapid in vitro diagnostics for microbiology, today announced the submission of its Accelerate WAVE™ system and positive blood culture gram-negative test kit to the U.S. Food and Drug Administration (FDA) for 510(k) clearance. The Accelerate WAVE system is designed to provide rapid antimicrobial susceptibility testing (AST) directly from positive blood culture bottles and bacterial isolate colonies. The WAVE system is designed to deliver accurate results in an average of 4.

      3/21/25 1:52:00 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2024 Financial Results

      TUCSON, Ariz., March 21, 2025 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today reports financial results for the fourth quarter and year ended December 31, 2024. 2024 Fourth Quarter Results Net sales for the quarter were $2.8 million, compared to $3.0 million for the same quarter of the prior year. The decline in revenues was primarily driven by lower sales of consumable products compared to the same period in the prior year.Gross margin was approximately 16% for the quarter, compared to approximately 21% for the same quarter of the prior year. The decline in

      3/21/25 8:30:00 AM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AXDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Shalhoub Paul Vincent

      3 - Accelerate Diagnostics, Inc (0000727207) (Issuer)

      5/1/25 6:40:09 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Chief Executive Officer Phillips Jack converted options into 53,283 shares and sold $16,473 worth of shares (25,343 units at $0.65), increasing direct ownership by 17% to 191,374 units (SEC Form 4)

      4 - Accelerate Diagnostics, Inc (0000727207) (Issuer)

      4/7/25 7:34:08 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Chief Technology Officer Mertz Larry Michael converted options into 4,298 shares and sold $990 worth of shares (1,523 units at $0.65), increasing direct ownership by 3% to 84,803 units (SEC Form 4)

      4 - Accelerate Diagnostics, Inc (0000727207) (Issuer)

      4/7/25 7:32:39 PM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AXDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Accelerate Diagnostics downgraded by Craig-Hallum with a new price target

      Craig-Hallum downgraded Accelerate Diagnostics from Buy to Hold and set a new price target of $5.00

      3/9/22 8:31:56 AM ET
      $AXDX
      Biotechnology: Laboratory Analytical Instruments
      Industrials